Lorvotuzumab mertansine

Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1].

Product Specifications

CAS Number

[1008106-64-6]

Product Name Alternative

IMGN-901; BB-1090

UNSPSC

12352100

Target

Antibody-Drug Conjugates (ADCs)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lorvotuzumab-mertansine.html

Purity

99.44

Solubility

10 mM in DMSO

Smiles

[Lorvotuzumabmertansine]

References & Citations

[1]Kathleen R Whiteman, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6 (2) :556-66.